Lorcainide

Lorcainide is a Class 1c antiarrhythmic agent. It was developed in the 1980s, but was withdrawn from potential use after clinical trials due to its severe side effects.

History

Lorcainide was developed in the 1980s as a potential treatment for arrhythmia. However, during clinical trials, it was found to have severe side effects, including an increased risk of death. This led to its withdrawal from further development.

Pharmacology

Lorcainide is a Class 1c antiarrhythmic agent. This class of drugs works by blocking the fast inward sodium channel, which slows the rate of rise of the action potential, thus decreasing the rate of depolarization. This has the effect of reducing the heart's susceptibility to arrhythmias.

Side Effects

The side effects of Lorcainide are severe and include an increased risk of death. Other side effects can include dizziness, nausea, and shortness of breath. Due to these side effects, Lorcainide was withdrawn from further development and is not currently used in clinical practice.

Clinical Trials

During clinical trials, Lorcainide was found to increase the risk of death in patients with a recent myocardial infarction. This led to its withdrawal from further development. The results of these trials have been used to inform the development of other antiarrhythmic drugs.

See Also

• Antiarrhythmic agent
• Myocardial infarction

Lorcainide Resources
Latest articles Most recent articles Ongoing trials	Wikipedia